Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

National Vision Holdings, Inc. - Common Stock (NQ:EYE)

22.60 -0.17 (-0.75%)
Streaming Delayed Price Updated: 11:47 AM EDT, Sep 10, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about National Vision Holdings, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
National Vision Holdings: Q1 Earnings Insights
 
Via Benzinga
National Vision Holdings, Inc. Reports First Quarter 2023 Financial Results
From National Vision Holdings, Inc.
Via Business Wire
Earnings Outlook For National Vision Holdings
 
Via Benzinga
National Vision Holdings, Inc. (NASDAQ:EYE) Long Term Shareholder Alert: Investigation over Possible Wrongdoing
San Diego, CA -- (SBWIRE) -- 05/04/2023 -- An investigation was announced concerning potential breaches of fiduciary duties by certain directors and officers of National Vision Holdings, Inc.. 
Via SBWire
NATIONAL VISION ALERT: Bragar Eagel & Squire, P.C. is Investigating National Vision Holdings, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
The Latest Analyst Ratings for National Vision Holdings
 
Via Benzinga
Looking Into National Vision Holdings's Return On Capital Employed
 
Via Benzinga
Where National Vision Holdings Stands With Analysts
 
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For May 2, 2023
 
Via Benzinga
National Vision Launches See Inside Collection to Highlight Mental Health Awareness
From National Vision, Inc.
Via Business Wire
National Vision Holdings, Inc. Announces First Quarter 2023 Earnings Release and Conference Call
From National Vision Holdings, Inc.
Via Business Wire
Toku Inc. Series A Preferred Investment Round Led by National Vision, Inc. and Topcon Healthcare
From National Vision, Inc.
Via Business Wire
Top 5 Consumer Stocks That Could Lead To Your Biggest Gains In April
The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against National Vision Holdings, Inc. (EYE)
From The Law Offices of Frank R. Cruz
Via Business Wire
Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Notifies National Vision Holdings, Inc. (EYE) Investors of Class Action and Last Few Hours to Actively Participate
From Bronstein, Gewirtz & Grossman, LLC
Via Business Wire
NATIONAL VISION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against National Vision Holdings, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Sotera, Argo, National Vision, and RYVYL and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NATIONAL VISION HOLDINGS, INC. (NASDAQ: EYE) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against National Vision Holdings, Inc. (NASDAQ: EYE)
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
NATIONAL VISION HOLDINGS, INC. (NASDAQ: EYE) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against National Vision Holdings, Inc. (NASDAQ: EYE)
From Bernstein Liebhard LLP
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National Vision, RYVYL, Invivyd, and Honda and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
National Vision Names 2022-2023 Scholarship Program Winners, Giving $12,500 to Next Generation of ODs
From National Vision, Inc.
Via Business Wire
Top 5 Consumer Stocks That May Rocket Higher
The most oversold stocks in the consumer discretionary sector presents an opportunity to buy into undervalued companies. 
Via Benzinga
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against National Vision, RYVYL, Invivyd, and Honda and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
This Analyst With 88% Accuracy Rate Sees Over 20% Upside In Marvell Technology - Here Are 5 Stock Picks For Last Week From Wall Street's Most Accurate Analysts
All the three major stock indices on the Wall Street jumped over 1% on Friday, with the tech-heavy Nasdaq rising around 2% on the last trading day of the week. 
Via Benzinga
NATIONAL VISION HOLDINGS, INC. (NASDAQ: EYE) SHAREHOLDER CLASS ACTION ALERT: Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against National Vision Holdings, Inc. (NASDAQ: EYE)
From Bernstein Liebhard LLP
Via GlobeNewswire
National Vision Holdings, Inc. Announces Participation in the UBS Global Consumer and Retail Conference
From National Vision Holdings, Inc.
Via Business Wire
Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Fate, Sotera, Argo, and National Vision and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Why National Vision Stock Crashed and Burned Wednesday
The optical specialist's results missed expectations and its guidance was even worse. 
Via The Motley Fool
Why Novavax Shares Are Trading Lower By Around 28%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Gainers Reata Pharmaceuticals Inc (NASDAQ: RETA) shares jumped 171.5% to $84.67 after the company reported the FDA approval of SKYCLARYS for patients with Friedreich's Ataxia. 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.